About UMass Boston and DF/HCC
UMass Boston is a Massachusetts public, urban university with an enrollment of 16,415. A Carnegie Research II university, UMass Boston is proudly the most diverse public four-year higher education institution in New England with 46% students of color. As a U.S. Department of Education Title III institution, 56% of UMass Boston undergraduate students are first-generation college students, 40% report speaking a language other than English at home, and 33% receive Pell grants. Promoting educational opportunity is at the core of UMass Boston’s mission. UMass Boston has made a strategic commitment and substantial investments to expanding and strengthening its research and training enterprise.
Dana-Farber/Harvard Cancer Center (DF/HCC), an NCI-designated comprehensive cancer center, was founded to integrate and build upon the collective talent and resources of the Harvard cancer research community. Five Boston academic medical institutions—Beth Israel Deaconess Medical Center, Boston Children’s Hospital, Brigham and Women’s Hospital, Dana-Farber Cancer Institute, and Massachusetts General Hospital—and two Harvard Schools—the Harvard Medical School and the Harvard T.H. Chan School of Public Health—combined their scientific strengths to create a rich, collaborative environment that transcends institutional borders. DF/HCC is the powerful successor organization to the Dana-Farber Cancer Institute Comprehensive Cancer Center, one of the original cancer centers designated by the NCI in 1973.
Today, more than 1,100 DF/HCC cancer researchers are working together in innovative clinical-, translational-, basic-, and population-based research programs. Our members receive in excess of $600 million in cancer research funding. Cost-effective shared facilities, or centralized core laboratories, enable access to cutting edge technologies and allow us to build world-class scientific archives. Our members are training and educating the next generation of cancer researchers. Thousands of patients are being enrolled in our clinical trials.
As one of the largest cancer research enterprises in the world, DF/HCC is committed to maximizing the impact of its research for cancer patients and ultimately realizing a world without cancer.
For potential U54 investigators, visit the DF/HCC Membership page for details to apply for membership.
The UMass Boston - Dana-Farber/Harvard Cancer Center